Amgen Safety Net Foundation

Understanding ASNF's Unique Structure

The Amgen Safety Net Foundation is not a traditional grant-making foundation and should not be approached as one. It operates as a corporate patient assistance program (PAP), functioning as Amgen Inc.'s primary vehicle for distributing free prescription drugs to low-income, uninsured, or underinsured patients across the United States. Amgen donates its pharmaceutical products to ASNF at no cost, and the foundation distributes those products directly to eligible patients. Total in-kind drug distribution reached $2.57 billion in FY2023, making ASNF one of the largest pharmaceutical PAPs in the country.

Who Can Benefit

ASNF does not award grants to organizations. The beneficiaries are individual patients who meet income and insurance eligibility criteria. However, healthcare organizations — safety-net clinics, federally qualified health centers (FQHCs), oncology practices, rheumatology departments, hospital social work teams, and patient advocacy groups — play a critical intermediary role. By developing internal workflows to identify eligible patients and facilitate ASNF enrollment, these organizations effectively expand patient access to $10,000-$80,000/year medications at no cost.

First-Time Applicants

Patients and providers new to ASNF should begin with a phone pre-screen at 1-800-932-3060 (Monday-Friday, 8 a.m.-8 p.m. ET) to confirm which Amgen medications are covered for the patient's condition and whether the patient's income falls within eligibility parameters. Income thresholds are tied to the Federal Poverty Level (FPL) and updated annually, so calling to confirm the current threshold before gathering documentation is critical.

Application Pathway

There is no LOI stage, no site visit, and no multi-stage proposal process. The application model is: eligibility pre-screen → patient application form (pages 1-4) → physician prescription (page 5) → income documentation → fax to 1-833-959-1409 or online submission at asnfapply.com → enrollment confirmation. The entire process can be completed within days when documentation is in order.

For Healthcare Organizations

Organizations seeking to leverage ASNF for their patient populations should designate a staff member — typically a social worker, pharmacist, or patient navigator — as the ASNF enrollment coordinator. No formal partnership agreement is required. Institutions that build systematic identification and enrollment processes generate significant value for their patients while reducing cost-of-care burdens.

In-Kind Drug Distribution at Billion-Dollar Scale

ASNF's giving is entirely in-kind pharmaceutical product distribution, not cash grants. The scale has grown dramatically over the past decade:

• FY2015: $86.9 million
• FY2019: $1.49 billion
• FY2020: $1.61 billion
• FY2021: $1.74 billion
• FY2022: $2.28 billion
• FY2023: $2.57 billion
• FY2024: Approx. $2.55 billion (per ProPublica's charitable activity calculation)

This 30-fold increase from 2015 to 2023 is driven almost entirely by Amgen's expanded portfolio of high-cost specialty biologics and biosimilars, not by a broadening of patient eligibility criteria. New products added since 2015 — Repatha ($5,900-$14,000/year), Aimovig ($6,900/year), Otezla ($30,000-$40,000/year), Lumakras ($20,000+/month), biosimilars at $3,000-$20,000/year — each carry list prices that inflate total in-kind value significantly when distributed free of charge.

Revenue and Asset Profile

Total revenue is 99.9% parent company contributions: $2.73 billion in FY2024, $2.41 billion in FY2023. Investment income is minimal ($2.0 million in 2023, $2.0 million in 2024), confirming this is not an endowed foundation. Total assets grew from $128.7M (2020) to $542.3M (2023) to $723.7M (2024), suggesting Amgen pre-capitalizes the foundation to absorb demand surges.

Therapeutic Area Distribution

No formal breakdown by area is disclosed in 990 filings, but the product portfolio implies: oncology (Neulasta, Blincyto, Kyprolis, Imlygic, Lumakras, Vectibix, Mvasi/bevacizumab, Kanjinti/trastuzumab, Riabni/rituximab) likely represents the highest-value segment given pricing; immunology/inflammatory disease (Enbrel, Otezla, Amjevita) is likely second by volume; bone health (Prolia, Xgeva, Evenity), cardiovascular (Repatha, Corlanor), nephrology (Parsabiv, Aranesp, Epogen), and hematology (N-Plate, Neupogen) complete the portfolio.

The Only Cash Grant

One cash grant appears in the 990 record: $10,001 to Heart to Heart International (Kansas) in FY2022 for 2,000 personal hygiene kits. This is an anomaly — no other organizational cash grants appear across any other year. Nonprofits should not treat this as evidence of a grant program.

The following table compares ASNF to its algorithmically-matched Health category peers from the foundation database. These peers are traditional grant-making foundations, not corporate PAPs — the structural contrast is instructive for grant seekers who may be searching for both types of Health funders.

ASNF is categorically different from every peer in this table. While Heartland Whole Health Institute, Bower Foundation, and similar foundations are endowed grant-makers distributing investment returns to health organizations, ASNF is a pass-through corporate entity converting parent-company drug inventory into patient assistance at a scale none of its algorithmic peers approach. ASNF's $723.7M in assets is the largest in the peer group, but its 'giving' of $2.57 billion exceeds peer annual giving by a factor of likely 50x or more. Grant seekers targeting Amgen Safety Net Foundation for organizational funding will not find a match here; those seeking to maximize patient access to specialty medications will find ASNF unmatched in scope.

Financial Trajectory (2019-2024)

ASNF's most recent IRS 990 was updated March 3, 2026, confirming FY2024 revenue of $2.73 billion — a 13% increase over FY2023's $2.41 billion. Assets reached $723.7 million in FY2024, recovering from a trough of $542.3 million in FY2023 (which reflected a period of elevated distribution relative to contributions). The foundation has shown consistent year-over-year growth in total distribution since 2019.

Drug Portfolio Expansion

The most significant recent additions to ASNF's covered product list include Tezspire (tezepelumab-ekko, approved 2021 for severe asthma), Amjevita (adalimumab-atto biosimilar, Amgen's version of Humira), and Lumakras (sotorasib, first approved KRAS G12C inhibitor for non-small cell lung cancer). These additions broaden patient access to treatments for previously underserved conditions including severe refractory asthma, NSCLC with KRAS mutation, and inflammatory bowel disease.

Leadership

Current leadership remains Amgen corporate officers: W Blair Fields (President), J Page Buchanan (Vice President), Alan Jamijian (Treasurer), Dennis Yai (Secretary), Andrea Robinson (Assistant Secretary). All report zero compensation. There is no independent board, confirming ASNF's role as a corporate instrument rather than an independent philanthropy. No leadership changes were announced publicly in 2025.

Infrastructure Investment

The asnfapply.com online portal represents a significant operational development, enabling provider-initiated applications without paper forms or fax, which accelerates enrollment for high-volume practices managing oncology or rheumatology patient panels.

Tip 1: This Is a Patient Assistance Program, Not a Grant

Organizations cannot apply for cash grants. The beneficiaries are patients. Healthcare organizations should approach ASNF as an enrollment partner, not a funder. Build internal capacity to identify eligible patients and submit applications on their behalf.

Tip 2: Pre-Screen Before Gathering Documents

Call 1-800-932-3060 before starting paperwork. ASNF staff will confirm: (a) whether the specific Amgen product the patient needs is currently covered, (b) what the income threshold is for that product, and (c) what documentation is required given the patient's insurance status. This call prevents wasted effort on applications that will be rejected on eligibility grounds.

Tip 3: Insurance Status Determines Application Pathway

ASNF has different criteria depending on whether the patient is uninsured, has private insurance, or has public coverage. The application instructions note that 'in addition to satisfying the general eligibility criteria, an applicant must meet additional criteria which are based on insurance coverage status.' Identify the correct pathway before completing the form.

Tip 4: Physician Participation Is Non-Negotiable

Page 5 of the paper application (the prescription section) must be completed and signed by the prescribing physician. Applications missing this section are rejected. When using the online portal at asnfapply.com, ensure the prescriber completes their portion before submission. Practices should designate a staff member to manage follow-up with physicians who have not completed their sections.

Tip 5: Geography-Adjusted Income Limits

Alaska residents qualify at income levels approximately 25% above the national FPL threshold; Hawaii residents at approximately 15% above. Always confirm the correct geographic adjustment — patients near these thresholds may be denied nationally but approved with the correct state-level calculation.

Tip 6: 12-Month Enrollment Cycle

Enrollment lasts up to 12 months. Re-enrollment is not automatic. For patients on chronic therapies (Enbrel, Prolia, Repatha), set a re-enrollment workflow at the 10-month mark to avoid any gap in supply. Lapsed enrollments for oncology patients can have immediate clinical consequences.

Tip 7: No Fee for Patients

ASNF charges patients nothing. Any third-party service that charges to 'help' with the application is not affiliated with ASNF.